JP2013501811A - 血小板産生を刺激するためのｅ５５０１の使用 - Google Patents

血小板産生を刺激するためのｅ５５０１の使用 Download PDF

Info

Publication number
JP2013501811A
JP2013501811A JP2012524897A JP2012524897A JP2013501811A JP 2013501811 A JP2013501811 A JP 2013501811A JP 2012524897 A JP2012524897 A JP 2012524897A JP 2012524897 A JP2012524897 A JP 2012524897A JP 2013501811 A JP2013501811 A JP 2013501811A
Authority
JP
Japan
Prior art keywords
subject
platelet
subjects
study
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012524897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501811A5 (enExample
Inventor
ジャン，ヤンジェン
Original Assignee
エーザイ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーザイ インコーポレーテッド filed Critical エーザイ インコーポレーテッド
Publication of JP2013501811A publication Critical patent/JP2013501811A/ja
Publication of JP2013501811A5 publication Critical patent/JP2013501811A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012524897A 2009-08-14 2010-08-13 血小板産生を刺激するためのｅ５５０１の使用 Pending JP2013501811A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23415309P 2009-08-14 2009-08-14
US61/234,153 2009-08-14
US36547910P 2010-07-19 2010-07-19
US61/365,479 2010-07-19
PCT/US2010/045433 WO2011019990A1 (en) 2009-08-14 2010-08-13 Use of e5501 for stimulating platelet production

Publications (2)

Publication Number Publication Date
JP2013501811A true JP2013501811A (ja) 2013-01-17
JP2013501811A5 JP2013501811A5 (enExample) 2013-08-01

Family

ID=42732726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012524897A Pending JP2013501811A (ja) 2009-08-14 2010-08-13 血小板産生を刺激するためのｅ５５０１の使用

Country Status (4)

Country Link
US (1) US20110166112A1 (enExample)
EP (1) EP2464352A1 (enExample)
JP (1) JP2013501811A (enExample)
WO (1) WO2011019990A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062233A1 (en) * 2002-01-18 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or salt thereof
WO2008021283A2 (en) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
KR19990008109A (ko) * 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CA2337755C (en) * 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
AU2003243921B2 (en) * 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US20040235834A1 (en) * 2003-03-25 2004-11-25 Farmer Luc J. Thiazoles useful as inhibitors of protein kinases
MXPA06000441A (es) * 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
EP1655291B1 (en) * 2003-08-12 2016-08-03 Shionogi & Co., Ltd. Compounds having thrombopoietin receptor agonism
EP1971368A4 (en) * 2005-11-08 2009-08-05 Astellas Pharma Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062233A1 (en) * 2002-01-18 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or salt thereof
WO2008021283A2 (en) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
JP2010500361A (ja) * 2006-08-08 2010-01-07 アカークス，インコーポレーテッド ヒトの血小板レベルを増加させるための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014026850; Ｗ．Ｆ．Ｒｏｓｓｅ，　Ｃｌｉｎｉｃｓ　ｉｎ　Ｈａｅｍａｔｏｌｏｇｙ，　１９８３，　１２（１），　ｐｐ２６７-２８４ *
JPN6014026851; Ｆ．Ｏｇａｓａｗａｒａ，　ｅｔ　ａｌ．，　Ｔｏｋａｉ　Ｊ　Ｅｘｐ　Ｃｌｉｎ　Ｍｅｄ．，　２００５，　３０（１），　ｐｐ４１-４８ *

Also Published As

Publication number Publication date
WO2011019990A1 (en) 2011-02-17
US20110166112A1 (en) 2011-07-07
EP2464352A1 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
St. Clair et al. Rituximab therapy for primary Sjögren's syndrome: an open‐label clinical trial and mechanistic analysis
Netto et al. Risk factors in burning mouth syndrome: a case–control study based on patient records
KR20230169458A (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
Choi et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP
JP2017521396A (ja) 癌のための併用療法
Rodriguez et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis
US20230181534A1 (en) Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancers
KR20250088633A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
SG182191A1 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
Kim et al. Nutritional risk factors are associated with postoperative complications after pancreaticoduodenectomy
JP2013501811A (ja) 血小板産生を刺激するためのｅ５５０１の使用
Salami et al. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
Miller et al. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors
Wang et al. Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation
Caimi et al. Non-Hodgkin’s lymphoma in the elderly
Uchida et al. Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
Casado et al. 4CPS-324 Effectiveness and safety of ixekizumab in moderate-to-severe plaque psoriasis
Gubler et al. Blood and blood treatments
Patel et al. Blood cancer: Advances in clinical research
WO2025242178A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
de-Cabo-López et al. Switching from ibrutinib to venetoclax in chronic lymphocytic leukemia: a management protocol based on clinical cases avoiding rapid disease progression Cambio de ibrutinib a venetoclax en la leucemia linfocítica crónica para evitar la progresión rápida de la enfermedad: un protocolo de transición
TW202545514A (zh) 杜洛希酊及化療藥物於製備用於治療或預防癌症之醫藥組成物的用途
Usui et al. Combined administration of low-dose predonisolone and cyclosporine in idiopathic membranous nephropathy: Tsukuba’s regimen for IMN
Bandt Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150127